Alzamend Neuro (ALZN) Issues Letter to Stockholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Alzamend Neuro Issues Letter to Stockholders
August 26, 2024 8:00 AM EDTAlzamend recently announced partnership with Massachusetts General Hospital for five phase II clinical trials of AL001, involving healthy human subjects and patients with Alzheimers, BD, MDD and PTSD Alzamend has executed an agreement to provide sufficient capital over the next 18 months to finance the initiation and progression of AL001 and ALZN002 clinical trials
ATLANTA--(BUSINESS WIRE)--... More
